Journal article

Elevated Levels of BRAF(V600) Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma

William Lu, Luciana Burton, James Larkin, Paul B Chapman, Paolo A Ascierto, Antoni Ribas, Caroline Robert, Jeffrey A Sosman, Grant A McArthur, Ilsung Chang, Ivor Caro, Elicia Penuel, Yibing Yan, Matthew J Wongchenko

JCO PRECISION ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018

Abstract

Purpose We performed a retrospective exploratory analysis to evaluate the prognostic and predictive effect of two circulating biomarkers, BRAFV600 mutant circulating tumor DNA (ctDNA) and circulating hepatocyte growth factor (cHGF), in metastatic melanoma. Materials and Methods This study evaluated patients from BRIM-3, a phase III trial comparing vemurafenib and dacarbazine in 675 patients with BRAFV600 mutated advanced melanoma. ctDNA was measured using droplet digital polymerase chain reaction, and cHGF was measured by enzyme-linked immunosorbent assay. Overall survival (OS) was estimated using the Kaplan-Meier method, and hazard ratios (HRs) were estimated using Cox proportional hazards ..

View full abstract

University of Melbourne Researchers